Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Therapy for High Immunologic Risk Renal Transplant Recipients
NCT00782821Phase 4Completed
- Sponsor
- University of Cincinnati
- Start
- Sep 2008
- Primary completion
- Feb 2013
- Modality
- Monoclonal Antibodies, Modified Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rituximab, bortezomib in kidney transplant rejection, sponsored by University of Cincinnati. Started Sep 2008; status: completed.
02
Drugs
rituximabbortezomib
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00782821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00782821.